Zobrazeno 1 - 10
of 20
pro vyhledávání: '"María F. Mercogliano"'
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 14, Iss 12, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/f97153e8a240450a80194174d2482fd7
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 13, Iss 5, Pp 1-14 (2022)
Abstract Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2. Due to TNBC heterogeneity
Externí odkaz:
https://doaj.org/article/c5cf687b8b084672a59b0ffb44e8ef9e
Autor:
Luciano Urdinez, Lorenzo Erra, Alejandro M. Palma, María F. Mercogliano, Julieta Belén Fernandez, Emma Prieto, Verónica Goris, Andrea Bernasconi, Marianela Sanz, Mariana Villa, Carolina Bouso, Lucia Caputi, Belen Quesada, Daniel Solis, Anabel Aguirre Bruzzo, Maria Martha Katsicas, Laura Galluzzo, Christian Weyersberg, Marcela Bocian, Maria Marta Bujan, Matías Oleastro, María B. Almejun, Silvia Danielian
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
CARD11-associated diseases are monogenic inborn errors of immunity involving immunodeficiency, predisposition to malignancy and immune dysregulation such as lymphoproliferation, inflammation, atopic and autoimmune manifestations. Defects in CARD11 ca
Externí odkaz:
https://doaj.org/article/75447857ce834becba913f9b9a7c680e
Autor:
Mara De Martino, Mercedes Tkach, Sofía Bruni, Darío Rocha, María F. Mercogliano, Mauro E. Cenciarini, María F. Chervo, Cecilia J. Proietti, Florent Dingli, Damarys Loew, Elmer A. Fernández, Patricia V. Elizalde, Eliane Piaggio, Roxana Schillaci
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Stat3 is constitutively activated in several tumor types and plays an essential role in maintaining their malignant phenotype and immunosupression. To take advantage of the promising antitumor activity of Stat3 targeting, it is vital to understand th
Externí odkaz:
https://doaj.org/article/304761e6292046bdad547449605fff86
Autor:
María F. Mercogliano, Gloria Inurrigarro, Mara De Martino, Leandro Venturutti, Martín A. Rivas, Rosalía Cordo-Russo, Cecilia J. Proietti, Elmer A. Fernández, Isabel Frahm, Sabrina Barchuk, Daniel H. Allemand, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G. Gercovich, Eduardo Cortese, Matías Amasino, Pablo Guzmán, Juan C. Roa, Patricia V. Elizalde, Roxana Schillaci
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Invasive micropapillary carcinoma of the breast (IMPC) is a histological tumor variant that occurs with low frequency characterized by an inside-out formation of tumor clusters with a pseudopapillary arrangement. IMPC is an aggres
Externí odkaz:
https://doaj.org/article/58b71ec24f974724a0c1d23b8fb44294
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::996f48f70c83a23c9e9ef6348b353e21
https://doi.org/10.1158/1078-0432.22465440
https://doi.org/10.1158/1078-0432.22465440
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure S1. Aggressive features of tumors overexpressing TNFα. A-C, H&E staining of BT-474 T2 tumors showing A, muscle and B, dermis infiltration (depicted by arrows). C, peritumor leukocyte infiltration (arrow). D, histopathological an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f53b3189418226eec43a4d093e1263
https://doi.org/10.1158/1078-0432.22465452.v1
https://doi.org/10.1158/1078-0432.22465452.v1
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure S2. Determination and scoring of MUC4 and TNFα expression in breast cancer biopsies by IHC. A, tissue microarrays were used to establish a score of MUC4 by IHC analysis as described by Workman et al (17). Score 0 represents no s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293fbb587e62fa5807a4b8437fd331e1
https://doi.org/10.1158/1078-0432.22465446
https://doi.org/10.1158/1078-0432.22465446
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Table S1. Patient baseline characteristics. Supplementary Table S2. Growth rate of TNFα-producing and control BT-474 tumors treated with trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ced8f81b9c8c9c4f054166936f6669b
https://doi.org/10.1158/1078-0432.22465455
https://doi.org/10.1158/1078-0432.22465455
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Purpose: Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We demonstrated that TNFα stimulation in vitro induces trastuzumab resistance in HER2-positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db77cf5fab880b8436f97ef09081e7a
https://doi.org/10.1158/1078-0432.c.6526023
https://doi.org/10.1158/1078-0432.c.6526023